To Our Forma Community:

Forma Therapeutics continues to closely monitor the COVID-19 pandemic situation and respond to the needs of our community. Together as a team, we are working to monitor guidance from health authorities, navigate the rapidly evolving environment and protect the health of our employees, patients and partners, as well as the communities in which we live and work. We have implemented a variety of efforts to mitigate the potential spread and impact of COVID-19.

Forma Colleagues
We are committed to ensuring the safety and well-being of our employees, the driving force behind our efforts to discover and develop life-changing therapies for patients. We have implemented a remote work policy for all employees that will continue until further notice. As lab-based drug discovery and development is a key element of Forma’s work, our goal is to bring researchers back to our labs as soon as possible, once appropriate safety measures are in place. Recognizing that each colleague has a unique situation, we’ve made employee assistance programs and professional support available during this challenging time. Several of our employees have family members who are providing medical care to people suffering from the virus in Massachusetts and elsewhere; for these and all Forma colleagues, we also provide regular updates and guidance to our employees to help them and their families stay safe and healthy during this time.

Patients and their Caregivers
We are focused on helping patients and their caregivers. In these uncertain times, we believe it is paramount to support people living with compromised immune systems and rare diseases in their efforts to maintain safe environments, as well as to provide continued access to information and resources. While many of Forma’s clinical trial sites have been temporarily impacted due to COVID-19, the sites are working in accordance with regional health authorities to evaluate the possibility of enrolling new patients based on local conditions. The Forma team maintains our steadfast commitment to advancing our pipeline of potential new therapies as soon as possible with patient and clinical site safety as our priority.

In addition, we are in contact with patient organizations, including the Sickle Cell Disease Association of America and other organizations and individuals, to keep an open dialogue around the impact of COVID on people living with rare hematologic diseases and cancers. During this challenging time, many of our colleagues are dedicated to finding ways in which we can help patients and their families.

Our Local Community
We recognize that this is a dynamic and challenging situation for everyone in our local community, and we have been finding ways to let them know that we are grateful for their work. From food and meal donations to law enforcement and hospital workers to cards for the elderly, we are proud to give back.
Re-entry Plans
In addition to staying informed about national and local guidelines and re-entry issues specific to our industry, Forma is considering a variety of ways to protect the health of our employees while continuing our work on behalf of patients. Although we miss the ease of in-person interactions with colleagues, we are finding other ways to stay connected and foster a culture of engagement and support by hosting regular virtual employee events for small and large groups. We look forward to returning to our offices and labs when it is safe to do so.

Despite the challenges that COVID-19 has presented, we are unrelenting in our drive to deliver meaningful therapies for patients. While our lives have been temporarily disrupted, our focus on our purpose remains steadfast. Please be well and be safe. We can do this.

Best,
Frank Lee
CEO, Forma Therapeutics